StockUS listing USNTHINASDAQHealthcareProfitless Growth

NeOnc Technologies Holdings, Inc. Common Stock(NTHI) Stock Analysis | Healthcare

USD --+0.00%
Reward54Moderate
Risk48Moderate
75%Data
Revenue down 100% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 141.66M
Reward Ratingⓘ54 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ48 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on NTHI to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is NeOnc Technologies Holdings, Inc. Common Stock?

, a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies.

AI Brief Pro

The brief on NeOnc Technologies Holdings, Inc. Common Stock

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is NeOnc Technologies Holdings, Inc. Common Stock?

, a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 141.66M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (54)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap141.66M
BetaN/A
Insider Activity
12M windowBullish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
0
860,700 shares
$337k
9-12months
0
16,000 shares
$39k